Nevro Corp. NVRO
At closeApr 2, 2025, 4:00 PM EDT
52-week range unavailable
- YTD
- +56.99%
- 1 year
- -54.12%
- Market cap
- 224.09M
- Revenue (ttm)
- 419.15M
- Profit margin
- -16.54%
- Shares out
- 37.47M
- Forward P/E
- -1.46
- YTD return
- +56.99%
- 1-year return
- -54.12%
- Volume
- 751.50K
- Open
- 5.84
- Previous close
- 5.84
- Day's range
- 5.84 – 5.86
- Beta
- 0.93
- Analysts
- Hold
- Price target
- 5.68 (-2.7%)
2Y -29.18 (-83.32%)
Key statistics
- Enterprise value
- 111.91M
- PEG ratio
- 0.00
- Price / sales
- 0.34
- Price / book
- 0.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -6.70%
- Free cash flow
- -24.21M
- Total cash
- 277.04M
- Total debt
- 246.93M
- Return on equity
- -24.78%
- Short % of float
- 8.62%
- 50-day average
- 4.67
- 200-day average
- 8.02
Analyst view
Consensus: hold
- Target (low)
- 4.00
- Target (mean)
- 5.68
- Target (high)
- 13.00
- Strong buy0
- Buy0
- Hold11
- Sell2
- Strong sell3
Next earnings
Consensus EPS estimate -0.76857.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2024 | Sep 1, 2024 | -0.82 | -0.51 | +0.31 | +37.80% |
| Aug 6, 2024 | Jun 1, 2024 | -0.63 | -0.43 | +0.20 | +31.75% |
| May 7, 2024 | Mar 1, 2024 | -1.02 | -0.70 | +0.32 | +31.37% |
| Feb 21, 2024 | Dec 1, 2023 | -0.50 | -0.15 | +0.35 | +70.00% |
| Nov 1, 2023 | Sep 1, 2023 | -0.77 | -0.65 | +0.12 | +15.58% |
| Aug 1, 2023 | Jun 1, 2023 | -0.68 | -0.69 | -0.01 | -1.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 18, 2024 | Truist Securities | main | Hold | Hold |
| Dec 11, 2024 | Citigroup | main | Neutral | Neutral |
| Dec 11, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Dec 9, 2024 | Canaccord Genuity | main | Hold | Hold |
| Dec 2, 2024 | Morgan Stanley | down | Equal-Weight | Underweight |
| Nov 12, 2024 | Canaccord Genuity | main | Hold | Hold |
About Nevro Corp.
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- nevro.com
News
NVRO Metals Advances Commercial Deployment of the NVRO Process™ Through Successful Continuous Production Demonstration on Hecla Greens Creek Material 
NVRO Metals Files Independent NI 43-101 Technical Report and Maiden Oxide Mineral Reserve Estimate for the NVRO Metals Hub 
NVRO Metals and Hecla sign an MOU to process 35,000-tonnes at the NVRO Metals Hub in the Northern Territory, Australia 
NVRO Metals Highlights Investment Potential of the NVRO Metals Hub Following Independent 77.6 Million-Tonne Mineral Resource Estimate 
NVRO Metals Announces Independent NI 43-101 Mineral Resource Estimate of 77.6 Million-Tonne Polymetallic Resource at the NVRO Metals Hub 
NVRO Metals Signs Heads of Agreement with Transamine for Proposed Copper Cathode Offtake and Financing Package of up to US$25 Million 
NVRO Metals Establishes the NVRO Metals Hub, Creating a Pathway to Critical Minerals Production and Accelerating Industrial Deployment of the NVRO Process™ 
CSE Bulletin: Delist - EnviroGold Global Limited (NVRO) 
Unlocking the Future of Metals Supply from Above-Ground Assets 
EnviroGold Advances NVRO Process™, Broadens Addressable Market
Your note
Sign in to keep a note on NVRO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DEMANE MICHAEL F | Director | Stock Award(Grant) | Sep 29, 2024 | 496,562 |
| FISCHER FRANK M | Director | Stock Award(Grant) | Mar 27, 2024 | 57,500 |
| GROSSMAN DONALD KEITH | Director | Stock Award(Grant) | May 22, 2024 | 230,613 |
| KOSARAJU SRIDHAR | Director | Stock Award(Grant) | Sep 29, 2024 | 42,342 |
| MCCORMICK SHAWN T | Director | Stock Award(Grant) | May 22, 2024 | 46,035 |
| O'BOYLE KEVIN C | Director | Stock Award(Grant) | May 22, 2024 | 43,396 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ArrowMark Colorado Holdings LLC | 11.72% | 4,391,258 | 16.56M | Sep 29, 2024 |
| Armistice Capital, LLC | 9.95% | 3,728,000 | 14.05M | Sep 29, 2024 |
| Blackrock Inc. | 8.19% | 3,067,206 | 11.56M | Sep 29, 2024 |
| Engaged Capital, LLC | 6.52% | 2,442,956 | 9.21M | Sep 29, 2024 |
| Vanguard Group Inc | 5.59% | 2,095,938 | 7.90M | Sep 29, 2024 |
| Braidwell LP | 4.53% | 1,698,768 | 6.40M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Explorer Fund, Inc. | 5.65% | 2,118,527 | 7.99M | Jul 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.08% | 1,152,806 | 4.35M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.52% | 943,680 | 3.56M | Oct 30, 2024 |
| Meridian Growth Fund | 1.69% | 633,748 | 2.39M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.53% | 574,034 | 2.16M | Sep 29, 2024 |
| Alger Weatherbie Specialized Growth Fund | 1.47% | 552,610 | 2.08M | Jul 30, 2024 |